You just read:

Lilly announces positive top-line results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head superiority study (SPIRIT-H2H) in patients with active psoriatic arthritis

News provided by

Eli Lilly Canada Inc.

Dec 17, 2018, 11:44 ET